Trial Profile

A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafasitamab (Primary) ; Cyclophosphamide; Doxorubicin; Lenalidomide; Parsaclisib; Prednisolone; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms J-MIND
Sponsors Incyte Biosciences Japan

06 Oct 2022 Planned End Date changed from 23 Jul 2026 to 20 Jul 2026.
06 Oct 2022 Planned primary completion date changed from 3 Jun 2025 to 31 May 2025.
23 Aug 2022 Planned number of patients changed from 49 to 65.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com